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pounds for modulating the function of a nicotinic acetyl-
choline receptor, and for the prevention and/or treatment of 
central nervous system disorders, substance use and/or 
abuse, and or gastrointestinal tract disorders. 
42 Claims, No Drawings 
US 9,649,301 B2 
1 
BIS-QUATERNARY AMMONIUM 
CYCLOPHANE COMPOUNDS THAT 
INTERACT WITH NEURONAL NICOTINIC 
ACETYLCHOLINE RECEPTORS 
2 
been estimated that over 90% of [3 H]NIC binding in the 
brain is due to association with the heteromeric receptor that 
is composed of a4 and ~2 subunits. Also abundant in the 
central nervous system are the homomeric receptors labeled 
CONTINUING APPLICATION DATA 
This application is a continuation of U.S. application Ser. 
No. 14/087,643, filed Nov. 22, 2013, which is a divisional of 
U.S. application Ser. No. 12/300,197, filed May 18, 2010, 
which is a national stage of International Application No. 
PCT/US2007/011269, filed May 11, 2007, which claims 
benefit of U.S. Provisional Application No. 60/799,881, filed 
May 12, 2006, which is incorporated herein by reference in 
its entirety. 
5 by [3H]methyllycaconitine (MLA), which has high affinity 
for the a7 nicotinic receptor subtype. Nicotinic receptor 
subtypes can be studied using functional assays, such as 
NIC-evoked neurotransmitter release (e.g., [3H]dopamine 
(DA) release, [3 H]norepinephrine (NE) release, [3 H]sero-
lO tonin (5-HT) release, [3H]ganmia-aminobutyric acid 
(GABA) release and [3 H]glutamate release) from super-
fused rat brain slices. Nicotinic receptors are located in the 
cell body and terminal areas of these neurotransmitter sys-
15 terns. NIC facilitates neurotransmitter release from nerve 
terminals. 
IDENTIFICATION OF FEDERAL FUNDING 
The present invention was supported by Grant NIH 
U19DA017548 from the National Institutes of Health, and 20 
therefore the government may have rights in the invention. 
FIELD OF THE INVENTION 
The structural and functional diversity of central nervous 
system nicotinic receptors has stimulated a great deal of 
interest in developing novel, subtype-selective agonists and/ 
or antagonists. Some of these agonists are currently being 
evaluated in clinical trials for cognitive enhancement and 
neuroprotective effects, potentially beneficial for disease 
states such as Alzheimer's and Parkinson's disease, as well 
as for treatment of drug abuse, depression, obesity and pain 
The invention relates to bis-quaternary ammonium cyclo-
phane compounds that interact with neuronal nicotinic 
receptors, and to methods of using the compounds to treat 
central nervous system diseases and pathologies. 
25 relief. 
SUMMARY OF THE INVENTION 
BACKGROUND OF THE INVENTION 
In one embodiment, compounds corresponding to the 
30 following structure are provided. 
S(-)-Nicotine (NIC) activates presynaptic and postsyn-
aptic neuronal nicotinic receptors that evoke the release of 
neurotransmitters from presynaptic terminals and that 
modulate the depolarization state of the postsynaptic neu- 35 
ronal membrane, respectively. Thus, nicotine produces its 
effect by binding to a family of ligand-gated ion channels, 
stimulated by acetylcholine (ACh) or nicotine which causes 
the ion channel to open and cations to flux with a resulting 
rapid (millisecond) depolarization of the target cell. 40 
Neuronal nicotinic receptors are composed of two types 
of subunits, a and ~' and assemble as heteromeric receptors 
with the general stoichiometry of 2a and 3~ or as homo-
meric receptors with 5a subunits. Nine subtypes of the a 
subunit (a2 to al0) and three subtypes of the~ unit (~2 to 45 
~4) are found in the central nervous system. The most 
common nicotinic receptor subtype in the brain is composed 
of two a4 and three ~2 subunits, i.e., a4~2. These subunits 
display different, but overlapping, patterns of expression in 
the brain. Examples of heteromeric receptor subtypes 50 
include a4~2, a3~2, a3~4, a6~2, a6~2~3, a4a5~2, 
a6a5~2, a6a4~2, a6a4~2~3, a4~2~4, a3~2~4, and oth-
ers. The predominant homomeric subtype includes a7, but 
other combinations have also been proposed. 
For the most part, the actual subunit compositions and 55 
stoichiometries of nicotinic receptors in the brain remain to 
be elucidated. Thus, neuronal nicotinic receptor subtype 
diversity originates from differences in the amino acid 
sequence at the subunit level and from the multiple combi-
nations of assemblies of subunits into functional receptor 60 
proteins, which affords a wide diversity of pharmacological 
specificity. 
In spite of the extensive diversity in neuronal nicotinic 
receptor messenger RNA expression, only a limited number 
of tools are available to study the pharmacology of native 65 
receptors. Radioligands are used in many studies. [3H]NIC 
appears to label the same sites in the brain as [3 H]ACh. It has 
(I) 
X18 and X28 are each independently an organic or 
inorganic anion. 
Q and Tare each independently attached to R1 and R2 . Q 
and T are each independently selected from alkyl, substi-
tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, sub-
stituted alkenyl, alkynyl, substituted alkynyl, aryl, substi-
tuted aryl, alkylaryl, substituted alkylaryl, arylalkyl, 
substituted arylalkyl, arylalkenyl, substituted arylalkenyl, 
arylalkynyl, substituted arylalkynyl, heterocyclic, substi-
tuted heterocyclic; SOY1 , SO2Y
1
, SO2OY
1 or SO2NHY
1
, 
where Y1 is selected from hydrogen, lower alkyl, alkenyl, 
alkynyl or aryl, and where Y1 is not hydrogen in SOY1 and 
if Y1 is alkenyl or alkynyl, the site of unsaturation is not 
conjugated with a heteroatom; COY2 , where Y2 is selected 
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substi-
tuted cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alky-
nyl, substituted alkynyl, aryl, substituted aryl, aryloxy, alky-
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, 
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, heterocyclic, or substituted heterocyclic, and 
where ifY2 comprises alkenyl or alkynyl, the site ofunsatu-
ration is not conjugated with the carbonyl group; OY3 , 
where Y3 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk-
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, het-
erocyclic, or substituted heterocyclic, where ifY3 comprises 
alkenyl or alkynyl, the site ofunsaturation is not conjugated 
US 9,649,301 B2 
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with the oxygen; NY4Ys, where Y4 and ys are each inde-
pendently selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk-
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, het-
erocyclic, or substituted heterocyclic, where if Y4 or ys 
comprises alkenyl or alkynyl, the site of unsaturation is not 
conjugated with the nitrogen; SY6, where Y6 is selected 
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substi-
tuted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, sub-
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, sub-
stituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
heterocyclic, or substituted heterocyclic, and where if Y6 
comprises alkenyl or alkynyl, the site of unsaturation is not 
conjugated with the sulfur. 
4 
absent, and when A6 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R13 and R14 are absent. 
A7 is carbon or nitrogen, provided that when A7 joins a 
ring atom with an unsaturated bond or is a nitrogen, R1s is 
5 absent, and when A7 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R1s and R16 are absent. 
A 8 is carbon or nitrogen, provided that when A 8 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 1 7 is 
absent, and when A8 joins a ring atom with an unsaturated 
10 bond and is a nitrogen, both R17 and R18 are absent. 
A9 is carbon or nitrogen, provided that when A9 joins a 
ring atom with an unsaturated bond or is a nitrogen, R19 is 
absent, and when A9 joins a ring atom with an unsaturated 
15 
bond and is a nitrogen, both R19 and R20 are absent. 
A 10 is carbon or nitrogen, provided that when A 10 joins a 
ring atom with an unsaturated bond or is a nitrogen, R21 is 
absent, and when A 10 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R21 and R22 are absent. 
R1 and R2 are each independently five or six membered 20 
rings as shown in formulas (IIA) and (IIB), wherein each 
ring of R 1 and R2 has one, two or three nitrogen atoms, each 
ring of R 1 and R 2 has one quatemized nitrogen, and two of 
A 11 is carbon or nitrogen, provided that when A 11 joins a 
ring atom with an unsaturated bond or is a nitrogen, R23 is 
absent, and whenA11 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R23 and R24 are absent. 
R3 throughR24 of eachR1 and two ofR3 throughR24 of each 
R2 are replaced by one attachment to Q and one attachment 
to T. 
(IIA) 
(IIB) 
A 1 is carbon or nitrogen, provided that when A 1 joins a 
ring atom with an unsaturated bond or is a nitrogen, R3 is 
absent, and when A 1 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R3 and R4 are absent. 
R3, R4, Rs, R6, R7, Rs, R9, R10, R11, R12, R13 and R14, or 
25 R1s, R16, R17, R1s, R19, R20, R21, R22, R23 and R24, when 
present, are each independently selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryl-
30 alkyl, substituted arylalkyl, arylalkenyl, substituted arylalk-
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, sub-
stituted heterocyclic, halo, cyano, nitro; or two adjacent 
groups R3 through R14, or groups R1s through R24, together 
35 
with the atoms to which they are attached on the ring of (IIA) 
or (IIB) independently form a three to eight member cyclol-
kane, substituted cycloalkane, cycloalkene, substituted 
cycloalkene, aryl, substituted aryl, heterocycle with one to 
three hetero atoms of nitrogen, oxygen or sulfur in the ring, 
40 or substituted heterocycle with one to three hetero atoms of 
nitrogen, oxygen or sulfur in the ring; and when all of the 
bonds to the ring ammonium nitrogen are saturated, then any 
ofR3, R4, Rs, R6, R7, R8, R9, R10, R11, R12, R13, R14, R1s, 
R16, R17, R1s, R19, R20, R21, R22, R23 or R24 which is 
45 attached to the ammonium nitrogen is a straight or branched 
alkyl group of four carbons or fewer. 
A2 is carbon or nitrogen, provided that when A2 joins a 50 
ring atom with an unsaturated bond or is a nitrogen, Rs is 
absent, and when A2 joins a ring atom with an unsaturated 
bond and is a nitrogen, both Rs and R6 are absent. 
In another embodiment, a composition is provided com-
prising a pharmaceutically acceptable carrier and a com-
pound as described above. 
In another embodiment, a method is provided for selec-
tively modulating the function of a nicotinic acetylcholine 
receptor comprising administering a therapeutically effec-
tive amount of a compound as described above to a mam-
malian subject in need thereof. A3 is carbon or nitrogen, provided that when A3 joins a 
ring atom with an unsaturated bond or is a nitrogen, R7 is 55 
absent, and when A3 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R7 and R8 are absent. 
In another embodiment, a method is provided for facili-
tating transport of a compound of the invention into the 
central nervous system by interaction of the compound with 
the blood brain barrier choline transporter. A 4 is carbon or nitrogen, provided that when A 4 joins a 
ring atom with an unsaturated bond or is a nitrogen, R9 is 
absent, and when A 4 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R9 and R 10 are absent. 
As is carbon or nitrogen, provided that when As joins a 
ring atom with an unsaturated bond or is a nitrogen, R 11 is 
absent, and when As joins a ring atom with an unsaturated 
bond and is a nitrogen, both R11 and R12 are absent. 
A 6 is carbon or nitrogen, provided that when A 6 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 13 is 
In another embodiment, a method is provided for pre-
60 venting and/or treating a central nervous system associated 
disorder, for example, schizophrenia, Tourettes', Hunting-
ton's Chorea, Parkinson's disease, Alzheimer's disease, and 
related conditions, comprising administering a therapeuti-
cally effective amount of a compound as described above to 
65 a mammalian subject in need thereof. 
In another embodiment, a method is provided for pre-
venting and/or treating substance use and/or abuse compris-
US 9,649,301 B2 
5 
ing administering a therapeutically effective amount of a 
compound as described above to a mammalian subject in 
need thereof. 
In another embodiment, a method is provided for pre-
venting and/or treating gastrointestinal tract disorders com- 5 
prising administering a therapeutically effective amount of a 
compound as described above to a mammalian subject in 
need thereof. 
6 
The term "central nervous system associated disorders" 
includes any cognitive, neurological, and mental disorders 
causing aberrant or pathological neural signal transmission, 
such as disorders associated with the alteration of normal 
neurotransmitter release in the brain. 
The term "lower alkyl" refers to straight or branched 
chain alkyl radicals having in the range of 1 to 4 carbon 
atoms. 
Other methods, features and advantages of the present 
invention will be or become apparent to one with skill in the 
art upon examination of the following detailed descriptions. 
It is intended that all such additional methods, features and 
advantages be included within this description, be within the 
scope of the present invention, and be protected by the 
accompanying claims. 
The term "alkyl" refers to straight or branched chain alkyl 
10 radicals having 1 to 19 carbon atoms, and "substituted alkyl" 
refers to alkyl radicals further bearing one or more substitu-
ents including, but not limited to, hydroxy, alkoxy ( of a 
lower alkyl group), mercapto ( of a lower alkyl group), aryl, 
15 
heterocyclic, halogen, trifluoromethyl, cyano, nitro, amino, 
carboxyl, carbamate, sulfonyl, and sulfonamide. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Before the present compositions and methods are 20 
described, it is to be understood that the invention is not 
limited to the particular methodologies, protocols, assays, 
and reagents described, as these may vary. It is also to be 
understood that the terminology used herein is intended to 
describe particular embodiments of the present invention, 25 
and is in no way intended to limit the scope of the present 
invention as set forth in the appended claims. 
The term "cycloalkyl" refers to cyclic ring-containing 
moieties containing 3 to 8 carbon atoms, and "substituted 
cycloalkyl" refers to cycloalkyl moieties further bearing one 
or more substituents as set forth above. 
The term "alkenyl" refers to straight or branched chain 
hydrocarbyl groups having at least one carbon-carbon 
double bond and having 2 to 19 carbon atoms, and "substi-
tuted alkenyl" refers to alkenyl groups further bearing one or 
more substituents as set forth above. 
The term "alkynyl" refers to straight or branched chain 
hydrocarbyl moieties having at least one carbon-carbon 
triple bond and having 2 to 19 carbon atoms, and "substi-
tuted alkynyl" refers to alkynyl moieties further bearing one 
It must be noted that as used herein and in the appended 
claims, the singular forms "a," "an," and "the" include plural 
references unless the context clearly dictates otherwise. 30 or more substituents as set forth above. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meanings as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs. All publications cited herein are incor-
porated herein by reference in their entirety for the purpose 35 
of describing and disclosing the methodologies, reagents, 
and tools reported in the publications that might be used in 
connection with the invention. Nothing herein is to be 
construed as an admission that the invention is not entitled 
to antedate such disclosure by virtue of prior invention. 40 
The term "aryl" refers to aromatic groups having 6 to 24 
carbon atoms, and "substituted aryl" refers to aryl groups 
further bearing one or more substituents as set forth above. 
The term "alkylaryl" refers to alkyl-substituted aryl 
groups, and "substituted alkylaryl" refers to alkylaryl groups 
further bearing one or more substituents as set forth above. 
The term "arylalkyl" refers to aryl-substituted alkyl 
groups, and "substituted arylalkyl" refers to arylalkyl groups 
further bearing one or more substituents as set forth above. 
The term "arylalkenyl" refers to aryl-substituted alkenyl 
groups, and "substituted arylalkenyl" refers to arylalkenyl 
groups further bearing one or more substituents as set forth 
above. 
The term "nicotinic acetylcholine receptor" refers to the 
endogenous acetylcholine receptor having binding sites for 
acetylcholine which also bind to nicotine. The term "nico-
tinic acetylcholine receptor" includes the term "neuronal 
nicotinic acetylcholine receptor." 
The term "arylalkynyl" refers to aryl-substituted alkynyl 
45 groups, and "substituted arylalkynyl" refers to arylalkynyl 
groups further bearing one or more substituents as set forth 
above. 
The terms "subtype of nicotinic acetylcholine receptor," 
and "nicotinic acetylcholine receptor subtype" refer to vari-
ous subunit combinations of the nicotinic acetylcholine 
receptor, and may refer to a particular homomeric or het-
eromeric complex, or multiple homomeric or heteromeric 50 
complexes. 
The term "choline transporter" refers to the endogenous 
choline transporter having binding sites for choline which 
also bind to positively charged quaternary ammonium 
groups. The term "choline transporter" includes the term 55 
"blood brain barrier choline transporter." 
The term "agonist" refers to a substance which interacts 
with a receptor and increases or prolongs a physiological 
response (i.e. activates the receptor). 
The term "partial agonist" refers to a substance which 60 
interacts with and activates a receptor to a lesser degree than 
an agonist. 
The term "heterocyclic" refers to cyclic moieties contain-
ing one or more heteroatoms as part of the ring structure and 
having 3 to 24 carbon atoms, and "substituted heterocyclic" 
refers to heterocyclic moieties further bearing one or more 
substituents as set forth above. 
The term "acyl" refers to alkyl-carbonyl groups, and 
"substituted acyl" refers to acyl groups further bearing one 
or more substituents as set forth above. 
The term "halogen" refers to fluoride, chloride, bromide 
or iodide groups. 
It is understood that in all substituted groups defined 
above, polymers arrived at by defining substituents with 
further substituents to themselves (e.g. substituted aryl hav-
ing a substituted aryl group as a substituent which is itself 
substituted with a substituted aryl group, etc.) are not 
intended for inclusion herein. In such cases, the maximum 
number of such substituents is three. That is to say that each 
The term "antagonist" refers to a substance which inter-
acts with and decreases the extent or duration of a physi-
ological response of that receptor. 
The terms "disorder," "disease," and "condition" are used 
inclusively and refer to any status deviating from normal. 
65 of the above definitions is constrained by a limitation that, 
for example, substituted aryl groups are limited to -substi-
tuted aryl-(substituted aryl)-substituted aryl. 
US 9,649,301 B2 
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Compounds of the present invention are bis-quaternary 
ammonium cyclophane compounds corresponding to For-
mula (I): 
(I) 
X18 and X28 are each independently an organic or 
inorganic anion. 
10 
Q and T are each independently attached to R 1 and R 2. Q 
and T are each independently selected from alkyl, substi-
15 
tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, sub-
stituted alkenyl, alkynyl, substituted alkynyl, aryl, substi-
tuted aryl, alkylaryl, substituted alkylaryl, arylalkyl, 
substituted arylalkyl, arylalkenyl, substituted arylalkenyl, 
arylalkynyl, substituted arylalkynyl, heterocyclic, substi- 20 
tuted heterocyclic; SOY1, SO2 Y1, SO2OY
1 or SO2NHY
1, 
where Y1 is selected from hydrogen, lower alkyl, alkenyl, 
alkynyl or aryl, and where Y1 is not hydrogen in SOY1 and 
if Y1 is alkenyl or alkynyl, the site of unsaturation is not 
conjugated with a heteroatom; COY2, where Y2 is selected 25 
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substi-
tuted cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alky-
nyl, substituted alkynyl, aryl, substituted aryl, aryloxy, alky-
laryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, 
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted 30 
arylalkynyl, heterocyclic, or substituted heterocyclic, and 
where ifY2 comprises alkenyl or alkynyl, the site ofunsatu-
ration is not conjugated with the carbonyl group; OY3, 
where Y3 is selected from hydrogen, alkyl, substituted alkyl, 
35 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk-
(IIA) 
(IIB) 
A 1 is carbon or nitrogen, provided that when A 1 joins a 
ring atom with an unsaturated bond or is a nitrogen, R3 is 
absent, and when A1 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R3 and R4 are absent. 
A2 is carbon or nitrogen, provided that when A2 joins a 
ring atom with an unsaturated bond or is a nitrogen, Rs is 
absent, and when A2 joins a ring atom with an unsaturated 
bond and is a nitrogen, both Rs and R6 are absent. 
A3 is carbon or nitrogen, provided that when A3 joins a 
ring atom with an unsaturated bond or is a nitrogen, R7 is 
absent, and when A3 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R7 and R8 are absent. 
A 4 is carbon or nitrogen, provided that when A 4 joins a 
ring atom with an unsaturated bond or is a nitrogen, R9 is 
absent, and when A4 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R9 and R 10 are absent. 
As is carbon or nitrogen, provided that when As joins a 
ring atom with an unsaturated bond or is a nitrogen, R 11 is 
absent, and when As joins a ring atom with an unsaturated 
bond and is a nitrogen, both R11 and R12 are absent. 
A 6 is carbon or nitrogen, provided that when A 6 joins a 
ring atom with an unsaturated bond or is a nitrogen, R13 is 
absent, and when A6 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R13 and R14 are absent. 
A7 is carbon or nitrogen, provided that when A7 joins a 
ring atom with an unsaturated bond or is a nitrogen, R1s is 
absent, and when A7 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R1s and R16 are absent. 
A 8 is carbon or nitrogen, provided that when A 8 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 1 7 is 
absent, and when A8 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R 1 7 and R 18 are absent. 
A9 is carbon or nitrogen, provided that when A9 joins a 
ring atom with an unsaturated bond or is a nitrogen, R19 is 
absent, and when A9 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R19 and R20 are absent. 
A 10 is carbon or nitrogen, provided that when A 10 joins a 
ring atom with an unsaturated bond or is a nitrogen, R21 is 
absent, and when A 10 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R21 and R22 are absent. 
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, het- 40 
erocyclic, or substituted heterocyclic, where ifY3 comprises 
alkenyl or alkynyl, the site ofunsaturation is not conjugated 
with the oxygen; NY4Ys, where Y4 and ys are each inde-
pendently selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk- 45 
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, het-
erocyclic, or substituted heterocyclic, where if Y4 or ys 50 
comprises alkenyl or alkynyl, the site of unsaturation is not 
conjugated with the nitrogen; SY6, where Y6 is selected 
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substi-
tuted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, sub-
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted 55 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, sub-
stituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
heterocyclic, or substituted heterocyclic, and where if Y6 
comprises alkenyl or alkynyl, the site of unsaturation is not 
conjugated with the sulfur. 
A 11 is carbon or nitrogen, provided that when A 11 joins a 
60 ring atom with an unsaturated bond or is a nitrogen, R23 is 
absent, and whenA11 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R23 and R24 are absent. 
R1 and R2 are each independently five or six membered 
rings as shown in formulas (IIA) and (IIB), wherein each 
ring of R 1 and R2 has one, two or three nitrogen atoms, each 
ring of R 1 and R 2 has one quaternized nitrogen, and two of 
R3 throughR24 of eachR1 and two ofR3 throughR24 of each 65 
R2 are replaced by one attachment to Q and one attachment 
to T. 
R3, R4, Rs, R6, R7, Rs, R9, R10, R11, R12, R13 and R14, or 
R1s, R16, R17, R1s, R19, R20, R21, R22, R23 and R24, when 
present, are each independently selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
US 9,649,301 B2 
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thiophene, indole, indolenine, isoindole, cyclopental[b ]pyri-
dine, pyrano[3,4-b ]pynrole, indazole, indoxazine, benzox-
azole, anthranil, naphthalene, tetralin, decalin, chromene, 
coumarin, chroman-4-one, isocoumarin, isochromen-3-one, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryl-
alkyl, substituted arylalkyl, arylalkenyl, substituted arylalk-
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, sub-
stituted heterocyclic, halo, cyano, nitro; or two adjacent 
groups R3 through R14, or groups R1s through R24, together 
with the atoms to which they are attached on the ring of (IIA) 
or (IIB) independently form a three to eight member cyclol-
kane, substituted cycloalkane, cycloalkene, substituted 
cycloalkene, aryl, substituted aryl, heterocycle with one to 
three hetero atoms of nitrogen, oxygen or sulfur in the ring, 
or substituted heterocycle with one to three hetero atoms of 
nitrogen, oxygen or sulfur in the ring; and when all of the 
bonds to the ring ammonium nitrogen are saturated, then any 
ofR3, R4, Rs, R6, R7, Rs, R9, R10, Ru, R12, R13, R14, R1s, 
R16, R17, R1s, R19, R20, R21, R22, R23 or R24 which is 
attached to the ammonium nitrogen is a straight or branched 
alkyl group of four carbons or fewer. 
5 quinoline, isoquinoline, cinnoline, quinazoline, naphthyr-
dine, pyrido[3,4-b ]-pyridine, pyridol[3,2-b ]pyridine, pyrido 
[ 4,3,-b ]-pyridine, benzoxazine, anthracene, phenanthrene, 
phenalene, fluorene, carazole, xanthene, acnidine, octa-
hydro-[1 ]pyridine, 1-methyloctahydro-[1 ]pyridine, octahy-
10 droindole, 1-methyloctahydroindole, octahydro-cyclopenta 
[b ]pyrrole, 1-methyloctahydro-cyclopenta[b ]pyrrole, 
decahydroquinoline, and 1-methyldecahydroquinoline. 
X18 and X28, for example, include F-, c1-, Br-, 1-, 
NO2 -, HSO4-, SO4-, HPO4-, Po/-, methanesulfonate, 
For example, R1 and R2 include pyrrole, pyrrolidine, 
pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, pyridine, 
pyrimidine, piperidine, quinoline, tetrahydroquinoline, iso-
quinoline, tetrahydroisoquinoline, pyrazine, piperazine, 
pyridazine and triazine. 
15 trifluromethane sulfate, p-toluenesulfonate, benzenesul-
fonate, salicylate, proprionate, ascorbate, aspartate, fumar-
ate, galactarate, maleate, citrate, glutamate, glycolate, lac-
tate, malate, maleate, tartrate, oxalate, succinate, or similar 
pharmaceutically acceptable organic acid addition salts, 
As another example, R3, R4, Rs, R6, R7, Rs, R9, R10, R11 , 
R12, R13, R14, R1s, R16, R17, R1s, R19, R20, R21, R22, R23 and 
20 including the pharmaceutically acceptable salts listed in the 
Journal of Pharmaceutical Sciences volume 66, page 2, 
1977, which are hereby incorporated by reference. The 
above salt forms may be in some cases hydrates or solvates 
R24, include hydrogen, methyl, ethyl, propyl, butyl, 25 
hydroxymethyl, hydroxyethyl, hydroxypropyl, trifluorom-
ethyl, chloro, bromo, phenyl, pyrrolidine, N-alkyl pyrroli-
dine (for example where the alkyl chain is methyl, ethyl or 
propyl), unsaturated pyrrolidine, unsaturated N-alkyl pyrro-
lidine (for example where the alkyl chain is methyl, ethyl or 30 
propyl), aziridine, N-methyl aziridine, azetidine, N-methyl 
azetidine, unsaturated azetidine, unsaturated N-methyl aze-
tidine, piperidine, N-methyl piperidine, unsaturated piperi-
dine, unsaturated N-methyl piperidine, azepane, N-methyl 
azepane, unsaturated azepane, unsaturated N-methyl 35 
azepane, azocane, N-methyl azocane, unsaturated azocane, 
unsaturated N-methyl azocane, l-aza-bicyclo[3.2.1 ]octane, 
l-aza-bicyclo[2.2.l]heptane, 8-methyl-8-aza-bicyclo[3.2.1] 
octane, l-aza-tricyclo[3.3. l. l 3.7]decane, methyl cycloalkyl, 
methyl substituted cycloalkyl, methyl pyrrolidine, methyl 40 
N-alkyl pyrrolidine (for example where the alkyl chain is 
methyl, ethyl or propyl), methyl unsaturated pyrrolidine, 
methyl unsaturated N-alkyl pyrrolidine (for example where 
the alkyl chain is methyl, ethyl or propyl), methyl aziridine, 
methyl N-methyl aziridine, methyl azetidine, methyl 45 
N-methyl azetidine, methyl unsaturated azetidine, methyl 
unsaturated N-methyl azetidine, methyl piperidine, methyl 
N-methyl piperidine, methyl unsaturated piperidine, methyl 
unsaturated N-methyl piperidine, methyl azepane, methyl 
N-methyl azepane, methyl unsaturated azepane, methyl 50 
unsaturated N-methyl azepane, methyl azocane, methyl 
N-methyl azocane, methyl unsaturated azocane, methyl 
unsaturated N-methyl azocane, methyl-1-aza-bicyclo[3.2.1] 
octane, methy 1-1-aza-bicyclo [2 .2 .1 ]heptane, 8-methyl-8-
aza-bicyclo [3 .2 .1 ]octane, and methyl-1-aza-tricyclo 55 
[3.3. l. l 3-7Jdecane. 
As a further example, when two adjacent groups R3 
through R14, or groups R1s through R24, together with the 
atoms to which they are attached on the ring of (IIA) or (IIB) 
independently form a three to eight member cyclolkane, 60 
substituted cycloalkane, cycloalkene, substituted cycloalk-
ene, aryl, substituted aryl, heterocycle with one to three 
hetero atoms of nitrogen, oxygen or sulfur in the ring, or 
substituted heterocycle with one to three hetero atoms of 
nitrogen, oxygen or sulfur in the ring. For example, possible 65 
rings include benzene, pyridine, pyran, indene, isoindene, 
benzofuran, isobenzofuran, benzo[b ]thiophene, benzo[ c] 
with alcohols and other solvents. 
In a compound of Formula (I), preferably R1 and R2 are 
six-membered, aromatic rings. More preferably, R1 and R2 
are pyridinium rings, such as 1,3-substituted pyridinium 
rings. 
In a compound of Formula (I), preferably R3 , R4 , Rs, R6 , 
R7, Rs, R9, R10, Ru, R12, R13, R14, R1s, R16, R17, R1s, R19, 
R20 , R21 , R22 , R23 or R24 is absent or is hydrogen. 
In a compound of Formula (I), preferably Q is attached to 
the nitrogen of a pyridinium ring of R1 and R2. In other 
preferred embodiments, Q is attached to the nitrogen of a 
pyridinium ring of R1 and a carbon at the 3-position of a 
pyridinium ring ofR2. Preferably, Q is an alkyl group; more 
preferably, Q is selected from -(CH2)4-, -(CH2)6-, 
-(CH2)s-, -(CH2)9-, -(CH2)10-, -(CH2)11-, and 
-(CH2)12--
In a compound of Formula (I), preferably Tis attached to 
the carbon at the 3-position of a pyridinium ring of R 1 and 
R2. In other preferred embodiments, T is attached to the 
nitrogen of a pyridinium ring of R2 and a carbon at the 
3-position of a pyridinium ring of R1. Preferably, Tis an 
alkyl group or a -C C-alkyl-C C- group; more pref-
erably, T is selected from -(CH2)12- or -C C 
-(CH2)6-C C-. 
In a compound of Formula (I), preferably X18 and X28 
are halogens. More preferably, X18 and X28 are bromide or 
iodide. 
In another embodiment, the compound of Formula (I) is 
defined wherein R1 and R2 are 1,3-substituted pyridinium 
rings, Q is -(CH2)4-, -(CH2)6-, -(CH2)s-, 
-(CH2)9-, -(CH2)10-, -(CH2)11- or -(CH2)12-, T 
is -(CH2)12- or ----C C-(CH2)6-C C-, and X
1 and 
X2 are bromide or iodide. 
Exemplary compounds of the present invention include: 
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-bis-
pyridinium diiodide; 
N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; 
N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-bis-
pyridinium dibromide; 
N,N'-(1, 1 0-decanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-bis-
pyridinium diiodide; 
N,N'-(1, 11-undecanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium dibromide; 
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N,N'-(l ,4-butanediyl)-3,3'-(1, 12-dodecanediyl)-bis-pyri-
dinium diiodide; 
N,3'-(1, 12-dodecanediyl)-3,N'-(1, 12-dodecanediyl)-bis-
pyridinium dibromide. 
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sodium-independent, carrier-mediated, and saturable pro-
cess. The choline transporter binding site contains an anionic 
binding area that binds positively charged quaternary ammo-
nium groups. Recent reports have shown that this transporter 
is efficacious in delivering quaternary ammonium analogs to 
the CNS. The quaternary annnonium structural characteris-
tic of the compounds of Formula (I) provides a unique 
synergistic combination of nicotinic receptor interaction and 
affinity for the blood brain barrier choline transporter to 
The compounds of the present invention may contain one 5 
or more stereocenters. The invention includes all possible 
diastereomers and all enantiomeric forms as well as all 
combinations of diasteriomers and enantiomers, including 
racemic mixtures. The compounds can be separated into 
substantially optically pure compounds. 10 maximize transport into the central nervous system. 
Compounds of the present invention can be prepared, for 
example, from corresponding bases by reaction with an 
appropriate alkyl bromide. 
The compounds of the invention are nicotinic acetylcho-
line receptor agents. Thus, they may augment or inhibit 
[
3H]nicotine binding, [3H]MLA binding, evoke or inhibit 
neurotransmitter release, and/or evoke or inhibit the flux of 
ions through the nicotinic receptor. Moreover, the com-
pounds of the invention may act either at presynaptic sites or 
postsynaptic sites, for example, at a postsynaptic acetylcho-
line receptor containing an a7 subunit. When acting at a 
postsynaptic site, neurotransmitter release per se is not 
altered. Rather, the compounds of the invention may act by 
interacting with a postsynaptic acetylcholine receptor to 
change the membrane potential of the cell, thereby increas-
ing or decreasing the likelihood of firing an action potential. 
Alternatively, interaction of a compound of the invention 
with a postsynaptic acetylcholine receptor may result in the 
alteration of one or more second messenger systems within 
the cell so as to decrease or increase the nicotinic cholinergic 
response. 
In one embodiment, the present invention relates to a 
method for selectively modulating the function of a nicotinic 
acetylcholine receptor comprising administering to a mam-
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or 
more subtypes ofnicotinic acetylcholine receptor. The com-
pound of Formula (I) may act as an agonist or partial agonist 
of nicotinic acetylcholine receptor function. Hence the com-
pound of Formula (I) may increase or prolong the release of 
a neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi-
nephrine, serotonin, gannna-aminobutryic acid, or gluta-
mate. Alternatively, the compound of Formula (I) may act as 
an antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
In another embodiment, the present invention is directed 
to a method for preventing and/or treating a central nervous 
system associated disorder comprising administering to a 
mammalian subject in need thereof a therapeutically effec-
15 tive amount of a compound of Formula (I). In such a 
method, the compound of Formula (I) may selectively bind 
to one or more subtypes of nicotinic acetylcholine receptor. 
The compound of Formula (I) may act as an agonist or 
partial agonist of nicotinic acetylcholine receptor function. 
20 Hence the compound of Formula (I) may increase or prolong 
the release of a neurotransmitter from a central nervous 
system tissue. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gannna-aminobutryic 
acid, or glutamate. Alternatively, the compound of Formula 
25 (I) may act as an antagonist of nicotinic acetylcholine 
receptor function. Hence the compound of Formula (I) may 
decrease the extent or duration of the release of a neurotrans-
mitter from a central nervous system tissue. In this regard, 
the compound of Formula (I) may act by decreasing stimu-
30 !ant-evoked neurotransmitter release. The neurotransmitter 
affected may include dopamine, norepinephrine, serotonin, 
gannna-aminobutryic acid, or glutamate. Alternatively, the 
compound of Formula (I) may act by interacting with a 
postsynaptic acetylcholine receptor to change the membrane 
35 potential of the cell thereby increasing or decreasing the 
likelihood of firing an action potential, or to alter one or 
more second messenger systems within the cell so as to 
decrease or increase the nicotinic cholinergic response. 
Central nervous system disorders which may be treated 
40 according to the method of the present invention include 
Alzheimer's disease, dementia, cognitive dysfunctions (in-
cluding disorders of attention, focus and concentration), 
attention deficit disorders, affective disorders, extrapyrami-
dal motor function disorders, Parkinson's disease, progres-
45 sive supramolecular palsy, Huntington's disease, Gilles de la 
Tourette syndrome, tardive dyskinesia, neuroendocrine dis-
orders, dysregulation of food intake, disorders of nocicep-
tion, pain, mood and emotional disorders, depression, panic or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of 
Formula (I) may act by decreasing stimulant-evoked neu- 50 
rotransmitter release. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-amin-
obutryic acid, or glutamate. Alternatively, the compound of 
Formula (I) may act by interacting with a postsynaptic 
acetylcholine receptor to change the membrane potential of 
the cell thereby increasing or decreasing the likelihood of 
firing an action potential, or to alter one or more second 
messenger systems within the cell so as to decrease or 
increase the nicotinic cholinergic response. 
anxiety, psychosis, schizophrenia, or epilepsy. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/or treating substance 
use and/or abuse comprising administering to a mannnalian 
subject in need thereof a therapeutically effective amount of 
a compound of Formula (I). In such a method, the compound 
55 of Formula (I) may selectively bind to one or more subtypes 
of nicotinic acetylcholine receptor. The compound of For-
mula (I) may act as an agonist or partial agonist of nicotinic 
acetylcholine receptor function. Hence the compound of 
Formula (I) may increase or prolong the release of a neu-
In another embodiment, the present invention is directed 
to a method of facilitating transport of a compound of 
Formula (I) into the central nervous system by interaction of 
the compound with the blood brain barrier choline trans-
porter. Compounds of Formula (I) have high affinity for 
blood brain barrier choline transporters and have the poten-
tial to be actively transported into the CNS by this trans-
porter. Choline transport at the blood brain barrier is a 
60 rotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi-
nephrine, serotonin, gamma-aminobutryic acid, or gluta-
mate. Alternatively, the compound of Formula (I) may act as 
an antagonist of nicotinic acetylcholine receptor function. 
65 Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of 
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from a peripheral nervous system tissue, or may act directly 
on a non-nervous system tissue. The neurotransmitter 
affected may include dopamine, norepinephrine, serotonin, 
ganmia-aminobutryic acid, or glutamate. Alternatively, the 
Formula (I) may act by decreasing stimulant-evoked neu-
rotransmitter release. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-amin-
obutryic acid, or glutamate. Alternatively, the compound of 
Formula (I) may act by interacting with a postsynaptic 
acetylcholine receptor to change the membrane potential of 
the cell thereby increasing or decreasing the likelihood of 
firing an action potential, or to alter one or more second 
messenger systems within the cell so as to decrease or 
increase the nicotinic cholinergic response. 
5 compound of Formula (I) may act as an antagonist of 
nicotinic acetylcholine receptor function. Hence the com-
pound of Formula (I) may decrease the extent or duration of 
the release of a neurotransmitter from a central nervous 
system tissue, or may decrease the extent or duration of the 
10 release of a neurotransmitter from a peripheral nervous 
system tissue, or may act directly on a non-nervous system 
tissue. In this regard, the compound of Formula (I) may act 
by decreasing stimulant-evoked neurotransmitter release. 
The conditions of substance use and/or abuse treated 
according to the method of the present invention include 
nicotine abuse (including use in smoking cessation therapy), 
nicotine intoxication, amphetamine abuse, methamphet-
amine abuse, MDMA (methylenedioxymethamphetamine) 15 
abuse, methylphenidate abuse, cocaine abuse, or alcohol 
abuse. 
In another embodiment, the present invention is directed 
The neurotransmitter affected may include dopamine, nor-
epinephrine, serotonin, gamma-aminobutryic acid, or gluta-
mate. Alternatively, the compound of Formula (I) may act by 
interacting with a postsynaptic acetylcholine receptor to 
change the membrane potential of the cell thereby increasing 
or decreasing the likelihood of firing an action potential, or to a method for preventing and/or treating gastrointestinal 
tract disorders comprising administering to a manmialian 
subject in need thereof a therapeutically effective amount of 
a compound of Formula (I). In such a method, the compound 
20 to alter one or more second messenger systems within the 
cell so as to decrease or increase the nicotinic cholinergic 
of Formula (I) may selectively bind to one or more subtypes 
of nicotinic acetylcholine receptor. The compound of For-
mula (I) may act as an agonist or partial agonist of nicotinic 25 
acetylcholine receptor function. Hence the compound of 
Formula (I) may increase or prolong the release of a neu-
rotransmitter from a central nervous system tissue, or may 
increase or prolong the release of a neurotransmitter from a 
peripheral nervous system tissue, or may act directly on a 30 
gastrointestinal tract tissue. The neurotransmitter affected 
may include dopamine, norepinephrine, serotonin, gamma-
aminobutryic acid, or glutamate. Alternatively, the com-
pound of Formula (I) may act as an antagonist of nicotinic 
acetylcholine receptor function. Hence the compound of 35 
Formula (I) may decrease the extent or duration of the 
release of a neurotransmitter from a central nervous system 
tissue, or may decrease the extent or duration of the release 
of a neurotransmitter from a peripheral nervous system 
tissue, or may act directly on a gastrointestinal tract tissue. 40 
In this regard, the compound of Formula (I) may act by 
decreasing stimulant-evoked neurotransmitter release. The 
neurotransmitter affected may include dopamine, norepi-
nephrine, serotonin, ganmia-aminobutryic acid, or gluta-
mate. Alternatively, the compound of Formula (I) may act by 45 
interacting with a postsynaptic acetylcholine receptor to 
change the membrane potential of the cell thereby increasing 
or decreasing the likelihood of firing an action potential, or 
to alter one or more second messenger systems within the 
cell so as to decrease or increase the nicotinic cholinergic 50 
response. 
response. 
Inflammatory disorders which may be treated according 
to the method of the present invention include adult respi-
ratory distress syndrome, allergy, anemia, ankylosing spon-
dylitis, asthma, atherosclerosis, bacterial infections, benign 
prostatic hyperplasia, cholecystitis, ulcerative colitis, 
Crohn's disease, diabetes mellitus, emphysema, gastritis, 
glomerulonephritis, hypereosinophilia, irritable bowel syn-
drome, multiple sclerosis, osteoarthritis, pancreatitis, poly-
myositis, psoriasis and rheumatoid arthritis. 
The compounds of the present invention can be delivered 
directly or in pharmaceutical compositions along with suit-
able carriers or excipients, as is well known in the art. For 
example, a pharmaceutical composition of the invention 
may include a conventional additive, such as a stabilizer, 
buffer, salt, preservative, filler, flavor enhancer and the like, 
as known to those skilled in the art. Exemplary buffers 
include phosphates, carbonates, citrates and the like. Exem-
plary preservatives include EDTA, EGTA, BHA, BHT and 
the like. 
An effective amount of such agents can readily be deter-
mined by routine experimentation, as can the most effective 
and convenient route of administration and the most appro-
priate formulation. Various formulations and drug delivery 
systems are available in the art. See, e.g., Gennaro, A. R., ed. 
(1995) Remington's Pharmaceutical Sciences. 
Suitable routes of administration may, for example, 
include oral, rectal, transmucosal, transdermal, topical, 
nasal, or intestinal administration and parenteral delivery, 
including intramuscular, subcutaneous, intramedullary 
injections, as well as intrathecal, direct intraventricular, 
intravenous, intraperitoneal, intranasal, or intraocular injec-
tions. In addition, the agent or composition thereof may be 
Gastrointestinal disorders which may be treated according 
to the method of the present invention include irritable 
bowel syndrome, colitis, diarrhea, constipation, gastric acid 
secretion or ulcers. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/or treating inflam-
matory tract disorders comprising administering to a mam-
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or 
more subtypes ofnicotinic acetylcholine receptor. The com-
pound of Formula (I) may act as an agonist or partial agonist 
of nicotinic acetylcholine receptor function. Hence the com-
pound of Formula (I) may increase or prolong the release of 
a neurotransmitter from a central nervous system tissue, or 
may increase or prolong the release of a neurotransmitter 
55 administered sublingually or via a spray, including a sub-
lingual tablet or a sublingual spray. The agent or composi-
tion thereof may be administered in a local rather than a 
systemic marmer. For example, a suitable agent can be 
delivered via injection or in a targeted drug delivery system, 
60 such as a depot or sustained release formulation. 
The pharmaceutical compositions of the present invention 
may be manufactured by any of the methods well-known in 
the art, such as by conventional mixing, dissolving, granu-
lating, dragee-making, levigating, emulsifying, encapsulat-
65 ing, entrapping, or lyophilizing processes. As noted above, 
the compositions of the present invention can include one or 
more physiologically acceptable carriers such as excipients 
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and auxiliaries that facilitate processing of active molecules 
into preparations for pharmaceutical use. 
Proper formulation is dependent upon the route of admin-
istration chosen. For injection, for example, the composition 
may be formulated in aqueous solutions, preferably in 5 
physiologically compatible buffers such as Hanks' solution, 
Ringer's solution, or physiological saline buffer. For trans-
mucosal or nasal administration, penetrants appropriate to 
the barrier to be permeated are used in the formulation. Such 
penetrants are generally known in the art. In a preferred 10 
embodiment of the present invention, the present com-
pounds are prepared in a formulation intended for oral 
administration. For oral administration, the compounds can 
be formulated readily by combining the active compounds 
with pharmaceutically acceptable carriers well known in the 15 
art. Such carriers enable the compounds of the invention to 
be formulated as tablets, pills, dragees, capsules, liquids, 
gels, syrups, slurries, suspensions and the like, for oral 
ingestion by a subject. The compounds may also be formu-
lated in rectal compositions such as suppositories or reten- 20 
tion enemas, e.g., containing conventional suppository bases 
such as cocoa butter or other glycerides. 
Pharmaceutical preparations for oral use can be obtained 
as solid excipients, optionally grinding a resulting mixture, 
and processing the mixture of granules, after adding suitable 25 
auxiliaries, if desired, to obtain tablets or dragee cores. 
Suitable excipients are, in particular, fillers such as sugars, 
including lactose, sucrose, marmitol, or sorbitol; cellulose 
preparations such as, for example, maize starch, wheat 
starch, rice starch, potato starch, gelatin, gum tragacanth, 30 
methyl cellulose, hydroxypropylmethyl-cellulose, sodium 
carboxymethylcellulose, and/or polyvinylpyrrolidone 
(PVP). If desired, disintegrating agents may be added, such 
as the cross-linked polyvinyl pyrrolidone, agar, or alginic 
acid or a salt thereof such as sodium alginate. Also, wetting 35 
agents such as sodium dodecyl sulfate may be included. 
Dragee cores are provided with suitable coatings. For this 
purpose, concentrated sugar solutions may be used, which 
may optionally contain gum arabic, talc, polyvinyl pyrroli-
done, carbopol gel, polyethylene glycol, and/or titanium 40 
dioxide, lacquer solutions, and suitable organic solvents or 
solvent mixtures. Dyestuffs or pigments may be added to the 
tablets or dragee coatings for identification or to characterize 
different combinations of active compound doses. 
Pharmaceutical preparations for oral administration 45 
include push-fit capsules made of gelatin, as well as soft, 
sealed capsules made of gelatin and a plasticizer, such as 
glycerol or sorbitol. The push-fit capsules can contain the 
active ingredients in admixture with filler such as lactose, 
binders such as starches, and/or lubricants such as talc or 50 
magnesium stearate and, optionally, stabilizers. In soft cap-
sules, the active compounds may be dissolved or suspended 
in suitable liquids, such as fatty oils, liquid paraffin, or liquid 
polyethylene glycols. In addition, stabilizers may be added. 
All formulations for oral administration should be in dos- 55 
ages suitable for such administration. 
16 
ered in the form of an aerosol spray presentation from 
pressurized packs or a nebulizer, with the use of a suitable 
propellant, e.g., dichlorodifluoromethane, trichlorofluo-
romethane, dichlorotetrafluoroethane, carbon dioxide, or 
any other suitable gas. In the case of a pressurized aerosol, 
the appropriate dosage unit may be determined by providing 
a valve to deliver a metered amount. Capsules and cartridges 
of, for example, gelatin, for use in an inhaler or insufllator 
may be formulated. These typically contain a powder mix of 
the compound and a suitable powder base such as lactose or 
starch. 
Compositions formulated for parenteral administration by 
injection, e.g., by bolus injection or continuous infusion can 
be presented in unit dosage form, e.g., in ampoules or in 
multi-dose containers, with an added preservative. The 
compositions may take such forms as suspensions, solu-
tions, or emulsions in oily or aqueous vehicles, and may 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Formulations for parenteral admin-
istration include aqueous solutions or other compositions in 
water-soluble form. 
Suspensions of the active compounds may also be pre-
pared as appropriate oily injection suspensions. Suitable 
lipophilic solvents or vehicles include fatty oils such as 
sesame oil and synthetic fatty acid esters, such as ethyl 
oleate or triglycerides, or liposomes. Aqueous injection 
suspensions may contain substances that increase the vis-
cosity of the suspension, such as sodium carboxymethyl 
cellulose, sorbitol, or dextran. Optionally, the suspension 
may also contain suitable stabilizers or agents that increase 
the solubility of the compounds to allow for the preparation 
of highly concentrated solutions. Alternatively, the active 
ingredient may be in powder form for constitution with a 
suitable vehicle, e.g., sterile pyrogen-free water, before use. 
As mentioned above, the compositions of the present 
invention may also be formulated as a depot preparation. 
Such long acting formulations may be administered by 
implantation (for example, subcutaneously or intramuscu-
larly) or by intramuscular injection. Thus, for example, the 
present compounds may be formulated with suitable poly-
meric or hydrophobic materials (for example as an emulsion 
in an acceptable oil) or ion exchange resins, or as sparingly 
soluble derivatives, for example, as a sparingly soluble salt. 
Suitable carriers for the hydrophobic molecules of the 
invention are well known in the art and include co-solvent 
systems comprising, for example, benzyl alcohol, a nonpolar 
surfactant, a water-miscible organic polymer, and an aque-
ous phase. The co-solvent system may be the VPD co-
solvent system. VPD is a solution of3% w/v benzyl alcohol, 
8% w/v of the nonpolar surfactant polysorbate 80, and 65% 
w/v polyethylene glycol 300, made up to volume in absolute 
ethanol. The VPD co-solvent system (VPD:5W) consists of 
VPD diluted 1: 1 with a 5% dextrose in water solution. This 
co-solvent system is effective in dissolving hydrophobic 
compounds and produces low toxicity upon systemic admin-
istration. Naturally, the proportions of a co-solvent system 
may be varied considerably without destroying its solubility 
and toxicity characteristics. Furthermore, the identity of the 
co-solvent components may be varied. For example, other 
In one embodiment, the compounds of the present inven-
tion can be administered transdermally, such as through a 
skin patch, or topically. In one aspect, the transdermal or 
topical formulations of the present invention can addition-
ally comprise one or multiple penetration enhancers or other 
effectors, including agents that enhance migration of the 
delivered compound. Transdermal or topical administration 
could be preferred, for example, in situations in which 
location specific delivery is desired. 
60 low-toxicity nonpolar surfactants may be used instead of 
polysorbate 80, the fraction size of polyethylene glycol may 
be varied, other biocompatible polymers may replace poly-
ethylene glycol, e.g., polyvinyl pyrrolidone, and other sug-
For administration by inhalation, the compounds for use 
according to the present invention are conveniently deliv-
65 
ars or polysaccharides may substitute for dextrose. 
Alternatively, other delivery systems for hydrophobic 
molecules may be employed. Liposomes and emulsions are 
well known examples of delivery vehicles or carriers for 
US 9,649,301 B2 
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hydrophobic drugs. Liposomal delivery systems are dis-
cussed above in the context of gene-delivery systems. Cer-
tain organic solvents such as dimethylsulfoxide also may be 
employed, although usually at the cost of greater toxicity. 
Additionally, the compounds may be delivered using sus- 5 
tained-release systems, such as semi-permeable matrices of 
solid hydrophobic polymers containing the effective amount 
of the composition to be administered. Various sustained-
release materials are established and available to those of 
skill in the art. Sustained-release capsules may, depending 10 
on their chemical nature, release the compounds for a few 
weeks up to over 100 days. Depending on the chemical 
nature and the biological stability of the therapeutic reagent, 
additional strategies for stabilization may be employed. 
For any composition used in the present methods of 15 
treatment, a therapeutically effective dose can be estimated 
initially using a variety of techniques well known in the art. 
For example, in a cell culture assay, a dose can be formu-
lated in animal models to achieve a circulating concentration 
range that includes the IC50 as determined in cell culture. 20 
Dosage ranges appropriate for human subjects can be deter-
mined, for example, using data obtained from cell culture 
assays and other animal studies. 
A therapeutically effective dose of an agent refers to that 
amount of the agent that results in amelioration of symptoms 25 
or a prolongation of survival in a subject. Toxicity and 
therapeutic efficacy of such molecules can be determined by 
standard pharmaceutical procedures in cell cultures or 
experimental animals, e.g., by determining the LD50 (the 
dose lethal to 50% of the population) and the ED50 (the dose 30 
therapeutically effective in 50% of the population). The dose 
ratio of toxic to therapeutic effects is the therapeutic index, 
which can be expressed as the ratio LD50/ED50 . Agents that 
exhibit high therapeutic indices are preferred. 
Dosages preferably fall within a range of circulating 35 
concentrations that includes the ED50 with little or no 
toxicity. Dosages may vary within this range depending 
upon the dosage form employed and the route of adminis-
tration utilized. The exact formulation, route of administra-
tion, and dosage should be chosen, according to methods 40 
known in the art, in view of the specifics of a subject's 
condition. 
The amount of agent or composition administered will, of 
course, be dependent on a variety of factors, including the 
sex, age, and weight of the subject being treated, the severity 45 
of the affliction, the marmer of administration, and the 
judgment of the prescribing physician. 
The present compositions may, if desired, be presented in 
a pack or dispenser device containing one or more unit 
dosage forms containing the active ingredient. Such a pack 50 
or device may, for example, comprise metal or plastic foil, 
such as a blister pack. The pack or dispenser device may be 
accompanied by instructions for administration. Composi-
tions comprising a compound of the invention formulated in 
a compatible pharmaceutical carrier may also be prepared, 55 
placed in an appropriate container, and labeled for treatment 
of an indicated condition. 
These and other embodiments of the present invention 
will readily occur to those of ordinary skill in the art in view 
of the disclosure herein, and are specifically contemplated. 60 
EXAMPLES 
The invention is further understood by reference to the 
following examples, which are intended to be purely exem- 65 
plary of the invention. The present invention is not limited 
in scope by the exemplified embodiments, which are 
18 
intended as illustrations of single aspects of the invention 
only. Any methods that are functionally equivalent are 
within the scope of the invention. Various modifications of 
the invention in addition to those described herein will 
become apparent to those skilled in the art from the fore-
going description. Such modifications fall within the scope 
of the appended claims. 
Example 1 
Preparation of Compound 
1, 10-bis-[ (pyridin-3-yl)]-1,9-decadiyne 
(YBr 
~--) 
N 
Pd(PPh3)2Cl2/Cul 
pyrrolidine 
1,9-Decanediyne (2.8 g, 20.9 mmol) and 3-bromopyridine 
(50 mmol) were mixed in pyrrolidine followed by the 
addition of Pd(PPh3 ) 2Cl2 (50 mg) and Cul (50 mg). The 
mixture was heated to 60-70° C. for 2 h. The solvent was 
removed in vacuum and the residue was subjected chroma-
tography. Hexane and ethyl acetate 10:1 elute out 3-bro-
mopyridine and 2:1 hexane and ethyl acetate elute out the 
product (5.1 g, 85% yield) as oil. HNMR (300 MHz, D20) 
8.59 (d, J=l.5 Hz, 2H), 8.43 (dd, J=l.8 Hz, J=5.1 Hz, 2H), 
7.62 (dt, J=l.8 Hz, J=7.8 Hz, 2H), 7.15 (ddd, J=0.9 Hz, J=4.8 
Hz, J=7.8 Hz, 2H), 2.40 (t, 1=6.9 Hz, 4H), 1.59-1.63 (m, 
4H), 1.46-1.49 (m, 4H). 
Example 2 
Preparation of Compound N,N'-(1,6-hexanediyl)-3, 
3'-(1,9-decanediyn-1, 10-diyl)-bis-pyridinium diio-
dide 
$ 
3,3'-(l,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol) 
and an equivalent of 1,6-diiodohexane were mixed in 
acetonitrile (1000 mL). The mixture was refluxed for 7 days. 
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19 
The solvent was removed in vacuum after cooling and the 
resulting residue was taken up in water and partitioned 
between ethyl ether and water. The aqueous layer was 
extracted extensively with ethyl ether remove the starting 
materials. Most of the water was removed and the residue 5 
was transferred into methanol. Methanol was removed and 
the product was dried under vacuum to afford the bis-
pyridinium cyclophane (30% yield). HNMR (300 MHz, 
D20) 8.76 (s, 2H), 8.56 (d, 1=6.0 Hz, 2H), 8.29 (d, 1=8.4 Hz, 
2H), 7.81 (dd, 1=6.3 Hz, 8.1 Hz, 2H), 4.40 (t, 1=7.5 Hz, 4H), 
10 
2.39 (t, 1=6.3 Hz, 4H), 1.85-1.84 (m, 4H), 1.49-1.52 (m, 
4H), 1.38-1.42 (m, 4H), 1.18-1.22 (m, 4H). CNMR, 146.97, 
146.26, 142.61, 128.00, 125.71, 101.43, 73.93, 61.99, 29.94, 
27.84, 27.49, 24.43, 18.90. 
20 
-continued 
_N 
@ 
\_ j Br
8 
\ 
3,3'-(l,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol) 
and an equivalent of 1,9-dibromononane were mixed in 
acetonitrile (1000 mL). The mixture was refluxed for 7 days. Example 3 
Preparation of Compound N,N'-(1,8-octanediyl)-3, 
3'-(1,9-decanediyn-1, 10-diyl)-bis-pyridinium diio-
dide 
15 The solvent was removed in vacuo after cooling and the 
resulting residue was taken up in water and partitioned 
between diethyl ether and water. The aqueous layer was 
extracted extensively with diethyl ether remove the starting 
20 
materials. Most of the water was removed and the residue 
was transferred into methanol. Methanol was removed and 
the product was dried under vacuum to afford the bis-
pyridinium cyclophane (38% yield) HNMR (300 MHz, 
D20) 10.39 (s, 2H), 9.52 (d, 1=5.7, 2H), 8.18 (d, 1=7.5, 8.00 
25 
(m, 2H), 5.06 (t, 1=7.2, 4H), 2.49 (t, 1=6.3, 4H), 2.08-2.18 
(br, 4H), 1.60-1.80 (br, 12H), 1.42-1.56 (br, SH), 1.37-1.40 
(br, 2H). 
30 
35 
Example 5 
Preparation of Compound N,N'-(1,10-decanediyl)-3, 
3'-(1,9-decanediyn-1, 10-diyl)-bis-pyridinium diio-
dide 
3,3'-(l ,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol) 
and an equivalent of 1,8-diiodooctane were mixed in 
acetonitrile (1000 mL). The mixture was refluxed for 7 days. 
The solvent was removed in vacuo after cooling and the 
resulting residue was taken up in water and partitioned 
between diethyl ether and water. The aqueous layer was 
extracted extensively with diethyl ether to remove the start-
ing materials. Most of the water was removed and the 45 
residue was transferred into methanol. Methanol was 
removed and dried under vacuum to afford the bis-pyri-
dinium cyclophane (35% yield). HNMR (300 MHz, D20) 
10.30 (s, 2H), 9.37 (d, 1=5.7, 2H), 8.19 (d, 1=8.1, 2H), 7.94 
(dd, 1=8.1, 1=6.0, 2H), 4.95 (t, 1=8.4, 4H), 2.49 (t, 1=6.6, 50 
4H), 2.14-2.22 (m, 4H), 1.75-1.85 (m, 4H), 1.61-1.68 (m, 
SH), 1.54-1.58 (br, SH), 1.49-4.58 (br, 4H). 
--
3,3'-(l,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol) 
and an equivalent of 1,10-diiododecane were mixed in 
acetonitrile (1000 mL). The mixture was refluxed for 7 days. 
The solvent was removed in vacuo after cooling and the 
Example 4 
Preparation of Compound N,N'-(1,9-nonanediyl)-3, 
3'-(1,9-decanediyn-1, 10-diyl)-bis-pyridinium di bro-
mide 
55 resulting residue was taken up in water and partitioned 
between diethyl ether and water. The aqueous layer was 
extracted extensively with diethyl ether remove the starting 
materials. Most of the water was removed and the residue 
was transferred into methanol. Methanol was removed and 
60 the product was dried under vacuum to afford the bis-
pyridinium cyclophane ( 40% yield). HNMR (300 MHz, 
D20), 10.11 (s, 2H), 9.37 (d, 1=6.3, 2H), 8.22 (dt, 1=7.8, 
l=l.2, 2H), 8.03 (dd, 1=6.3, 1=7.8, 2H), 4.99 (t, 1=8.1, 4H), 
2.49 (t, 1=6.6, 4H), 2.15-2.17 (m, 4H), 1.38-1.75 (m, 24H). 
65 CNMR, 147.73, 145.88, 142.71, 128.04, 126.46, 102.54, 
74.29, 61.82, 32.44, 28.71, 27.90, 27.83, 27.40, 25.81, 
20.21. 
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Example 6 
Preparation of Compound N,N'-(1,11-unde-
canediyl)-3,3'-(1,9-decanediyn-1, 10-diyl)-bis-pyri-
dinium dibromide 
0 
Br 
0 
Br 
=-
22 
brine (3x40 mL) and saturated brine ( 40 mL), dried over 
anhydrous Na2 SO4 , and concentrated under reduced pres-
sure. The crude product was purified by column chroma-
tography (hexanes:ethylacetate 2: 1 to 1: 1) to afford 3.98 g of 
5 the title compound. Yield: 75%. 
1H NMR (300 MHz, 
CDC13 ) Ii 1.17-1.40 (m, 16H), 1.53-1.68 (m, 4H), 2.60 (t, 
J=7.5 Hz, 4H), 7.20 (dd, J=7.8, 1.8 Hz, 2H), 7.48 (dt, J=7.8, 
1.8 Hz, 2H), 8.43 (d, J=5.1 Hz, 2H), 8.44 (s, 2H) ppm; 13C 
NMR (75 MHz, CDC13 ) ll 29.4, 29.7, 29.8, 29.9, 31.4, 33.3, 
10 
123.3, 135.8, 138.4, 147.2, 150.0 ppm. 
15 
20 
Example 8 
Preparation of Compound N,N'-(1,4-butanediyl)-3, 
3'-(1,12-dodecanediyl)-bis-pyridinium diiodide 
N 
,P' 
--
3,3'-(l ,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol) 
and an equivalent of 1,11-dibromoundecane were mixed in 
25 
acetonitrile (1000 mL). The mixture was refluxed for 7 days. 
The solvent was removed in vacuo after cooling and the 
resulting residue was taken up in water and partitioned 
between diethyl ether and water. The aqueous layer was 
extracted extensively with diethyl ether remove the starting 
30 
materials. Most of the water was removed and the residue 
was transferred into methanol. Methanol was removed and 
the product was dried under vacuum to afford the bis-
pyridinium cyclophane (42% yield). HNMR (300 MHz, 
D2 O), 9.92 (s, 2H), 9.48 (d, J=7.8, 2H), 8.22 (d, J=S.1, 2H), 35 
8.05 (m, 2H), 5.08 (br, 4H), 2.49 (t, J=6.3, 4H), 2.05-2.15 
(br, 4H), 1.70-1.82 (br, 12H), 1.55-1.65 (br, 4H), 1.45-1.55 
(br, 4H), 1.30-1.45 (SH). 
( 
N 
0~ 
3,3'-(Dodecan-1,12-diyl)-bis-pyridine (1 mmol) and an 
equivalent of 1,4-diiodobutane were mixed in 4-methyl-2-
pentanol (265 mL). The mixture was refluxed for 28 days. 
u 
N 
Br 
Example 7 
Preparation of Compound 
1, 12-bis-(pyridin-3-yl)-dodecane 
--Br 
LDA (2M) (20.40 mL, 40.80 mmol) was added drop-wise 
40 The solvent was removed in vacuo after cooling and the 
resulting residue was taken up in methylene chloride and 
water ( 50 mL, 1: 1 ). The methylene chloride layer containing 
the mono-quaternary ammonium product was removed and 
the remaining aqueous layer further extracted with methyl-
45 ene chloride (3x25 mL). The water layer containing the 
bis-pyridinium product was evaporated under reduced pres-
sure to low volume (0.5 mL) and transferred into methanol 
(5 mL). The methanol was removed and the product was 
dried under vacuum to afford the bis-pyridinium cyclophane 
(35% yield). 1H NMR (300 MHz, CD3 OD) ll 1.21-1.46 (m, 
50 16H), 1.72 (m, 4H), 2.18 (m, 4H), 2.56 (s, 6H), 2.81 (t, J=7.5 
Hz, 4H), 4.68 (m, 4H), 8.28 (s, 2H), 8.79 (s, 2H), 8.83 (s, 
2H) ppm; 13C NMR (75 MHz, CD3 OD) ll 18.8, 28.8, 28.9, 
29.4, 29.6, 30.8, 33.5, 61.7, 140.9, 142.3, 143.3, 144.9, 
147.6 ppm. 
55 
Example 9 
Preparation of Compound 
12-(pyridin-3-yl)-1-bromododecane 
to a solution of 3-picoline (3.80 g, 40.80 mmol) in THF (60 60 
mL) at -78° C. The mixture was stirred for 30 min and then 
1,10-dibromodecane (6.43 g, 16.32 mmol) in THF (10 mL) 
was added drop-wise. The resulting mixture was warmed to 
room temperature and stirred for 4 hrs. Fifty percent satu-
rated NH4Cl was added to the reaction mixture. The aqueous 
phase was extracted with ethylacetate (2x40 mL), and the 
combined organic liquors were washed with 50% saturated 
65u + 
N 
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-continued 
Br 
LDA (2 M) (10.5 mL, 21.22 mmol) was added drop-wise 
to a solution of 3-picoline (2.17 g, 23.34 mmol) in THF (60 
mL) at -78° C. The mixture was stirred for 30 min and then 
1,11-dibromoundecane (10 g, 31.83 mmol) was added in one 
portion. The resulting mixture was warmed to 0° C. and 
stirred for 4 hrs. Fifty percent saturated NH4Cl was added to 
the reaction mixture. The aqueous phase was extracted with 
ethylacetate (2x40 mL), and the combined organic liquors 
were washed with 50% saturated brine (3x40 mL) and 
saturated brine (40 mL), dried over anhydrous Na2 SO4 , and 
concentrated under reduced pressure. The crude product was 
purified by colunm chromatography (hexanes:ethylacetate 
4:1) to afford 4.47 g 12-(pyridin-3-yl)-1-bromododecane. 
Yield: 59%. 
Example 10 
Preparation of Compound N,3'-(1,12-dodecanediyl)-
3,N'-(1, 12-dodecanediyl)-bis-pyridinium dibromide 
12-(Pyridin-3-yl)-1-bromododecane was dissolved in 
acetonitrile (250 mL). The mixture was refluxed for 24 
hours. The solvent was removed in vacuo after cooling and 
the resulting residue was taken up by water and diethyl ether 
(50 mL, 1:1). The diethyl ether layer containing the starting 
material was removed and the remaining aqueous layer 
further extracted with diethyl ether (3x25 mL). The water 
layer containing the bis-pyridinium product was evaporated 
under reduced pressure to low volume (0.5 mL) and trans-
ferred into methanol (5 mL). The methanol was removed 
and the product was dried under vacuum to afford the 
bis-pyridinium cyclophane (25% yield). 1 H NMR (300 
MHz, DMSO-d6 ) Ii 1.15-1.39 (m, 32H), 1.63 (m, 4H), 1.90 
(m, 4H), 2.78 (t, J=7.8 Hz, 4H), 4.57 (t, J=7.2 Hz, 4H), 8.08 
(dd, J=8.1, 6.0 Hz, 2H), 8.48 (d, J=8.1 Hz, 2H), 8.98 (d, 
1=6.0 Hz, 2H), 9.10 (s, 2H) ppm; 13C NMR (75 MHz, 
CD3 OD) Ii 25.5, 28.5, 28.8, 28.9, 29.0, 29.9, 30.7, 31.7, 
60.5, 127.4, 142.1, 142.8, 143.8, 144.9 ppm. 
Example 11 
Inhibition of [3H]nicotine and 
[
3 H]Methyllycaconitine Binding Assays 
Whole brain, excluding cortex and cerebellum, was 
homogenized in 20 vol of ice-cold buffer, containing (in 
24 
mM): 2 HEPES, 11.8 NaCl, 0.48 KC!, 0.25 CaCl2 and 0.12 
MgSO4 , pH 7.5. Homogenate was centrifuged (25,000 g, 15 
min, 4° C.). Pellets were resuspended in 20 vol buffer and 
incubated at 37° C., for 10 min, cooled to 4° C. and 
5 centrifuged (25,000 g, 15 min, 4° C.). Pellets were resus-
pended and centrifuged using the same conditions. Final 
pellets were stored in assay buffer, containing (in mM): 20 
HEPES, 118 NaCl, 4.8 KC!, 2.5 CaCl2 , and 1.2 MgSO4 , pH 
7 .5 at - 70° C. Upon use, final pellets were resuspended in 
10 -20 vol assay buffer. Samples (250 µ!) contained 100-140 µg 
of membrane protein, 3 nM [3H]nicotine or 3 nM [3 H] 
methyllycaconitine (MLA), and bis-quaternary ammonium 
cyclophane analog (100 nM) in assay buffer containing 50 
mM Tris. Control was in the absence of analog. In [3 H] 
15 nicotine and [3H]methyllycaconitine binding assays, non-
specific binding was determined in the presence of 10 µM 
cytisine and 10 µM nicotine, respectively. Incubations pro-
ceeded for 60 min at room temperature using 96-well plates 
and were terminated by harvesting on Unifilter-96 GF/B 
20 filter plates presoaked in 0.5% polyethylenimine, using a 
Packard FilterMate harvester. After washing 5 times with 
350 µI ice-cold assay buffer, filter plates were dried (60 min, 
4° C.), bottom-sealed, and filled with Packard's MicroScint 
20 cocktail ( 40 µI/well). After 60 min, filter plates were 
25 top-sealed, and radioactivity determined using a Packard 
TopCount. Protein concentrations were determined using the 
Bradford dye-binding procedure bovine serum albumin as 
the standard. The results are summarized in Table 1. 
30 Example 12 
Inhibition of Nicotine-Evoked [3 H]Neurotransmitter 
Release Assay 
35 Rat striatal slices (500 µm thickness, 6-8 mg wet weight) 
were incubated for 30 minutes in Krebs buffer (118 mM 
NaCl, 4.7 mM KC!, 1.2 mM MgCl2 , 1.0 mM NaH2 PO4 , 1.3 
mM CaCl2 , 11.1 mM glucose, 25 mM NaHCO3 , 0.11 mM 
L-ascorbic acid, and 0.004 mM disodium EDTA; pH 7.4, 
40 and saturated with 95% 0/5% CO2) in a metabolic shaker 
at 34 ° C. Slices were rinsed with 15 mL of fresh buffer and 
incubated for an additional 30 minutes in fresh buffer 
containing 0.1 µM [3H]dopamine (DA; 6 slices/3 mL). 
Subsequently, slices were rinsed with 15 mL of fresh buffer 
45 and transferred to a glass superfusion chamber. Slices were 
superfused (1.0 mL/min) for 60 minutes with Krebs buffer 
containing nomifensine (10 µM) and pargyline (10 µM) and 
maintained at 34° C., pH 7.4, with continual aeration (95% 
0 2/5% CO2). Two five minute samples (5 mL each) were 
50 collected to determine basal outflow of [3 H]DA. The bis-
quaternary ammonium cyclophane analogs were added to 
the superfusion buffer after the collection of the second 
sample and remained in the buffer until 12 consecutive five 
minute samples were collected. Subsequently, S-( - )-nico-
55 tine (10 µM) was added to the buffer and an additional 12 
consecutive five minute samples were collected. At the end 
of the experiment, each slice was solubilized and the [3 H] 
content of the tissue determined. 
Radioactivity in the superfusate and tissue samples was 
60 determined by liquid scintillation spectroscopy. Fractional 
release for tritium collected in each sample was divided by 
the total tritium present in the tissue at the time of sample 
collection and was expressed as a percentage of total tritium. 
Basal [3H]outflow was calculated from the average of the 
65 tritium collected in the two five minute samples just before 
addition of the quaternary ammonium analog. The sum of 
the increase in collected tritium resulting from either expo-
US 9,649,301 B2 
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sure to the test compound or exposure to S-(-)-nicotine in 
the absence and presence of the test compound equaled total 
[
3H]overflow. [3 H]Overflow was calculated by subtracting 
the [3H]outflow during an equivalent period of prestimula-
tion from the values in samples collected during and after 5 
drug exposure. Inasmuch as the radiolabelled compounds 
were not separated and identified, the tritium collected in 
superfusate is referred to as either [3 H]outflow or [3 H] 
overflow, rather than as [3 H]DA. [3 H]Overflow primarily 
represents [3 H]DA in the presence of nomifensine and 10 
pargyline in the superfusion buffer. 
The bis-quaternary ammonium cyclophane analogs were 
evaluated for their ability to evoke [3 H]DA release from rat 
striatal slices. In addition, the classical competitive nicotinic 
antagonist DH~E was also examined in this assay for 
26 
comparison. None of the compounds examined had any 
significant [3H]DA releasing properties in this assay in the 
concentration range tested. 
The bis-quaternary ammonium cyclophane analogs were 
also evaluated for their ability to inhibit nicotine evoked 
[
3 H]DArelease. In these experiments, the striatal slices were 
superfused for 60 minutes with 100 nM concentration of the 
bis-quaternary ammonium cyclophane analogs prior to nico-
tine (10 µM) exposure. Antagonist activity was evaluated by 
comparing the nicotine evoked [3 H]overflow in the absence 
and presence of the analogs. The relative order of potency of 
the bis-quaternary ammonium cyclophane analogs for inhi-
bition of nicotine-evoked [3H]DA release from rat striatal 
slices is illustrated in Table 1. 
TABLE 1 
Bis-Quaternary Ammonium Cyclophane Compounds: Affinity for the BBB 
COMPOUND 
Example 2 
Example 3 
Example 4 
Choline Transporter, Inhibition of [3H]Nicotine and [3 H]Methyllycaconitine (MLA) Binding to 
Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked [3H]Dopamine Release from 
Superfused Rat Striatal Slices 
Affinity for the 
Inhibition of 
Nicotine-
BBB choline Inhibition of Inhibition of evoked 
transporter Ki [3 H]Nicotine [3H]MLA [ 3H]DA 
(µM) bindinga Bindinl releasec 
33.6 7% 2% ND 
ND 9% 0% ND 
1.4 0% 3% ND 
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COMPOUND 
Example 5 
Example 6 
N 
::::--(f) 
Br0 
~ /2 
~ 
Example 8 
Example 10 
TABLE I-continued 
Bis-Quaternary Ammonium Cyclophane Compounds: Affinity for the BBB 
Choline Transporter, Inhibition of [3H]Nicotine and [3 H]Methyllycaconitine (MLA) Binding to 
Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked [3H]Dopamine Release from 
Su erfused Rat Striatal Slices 
Affinity for the 
BBB choline Inhibition of Inhibition of 
transporter Ki [ 3H]Nicotine [3 H]MLA 
(µM) bindinga Bindingb 
0.8 0.55 (Ki, 4.64 (Ki, 
µM) µM) 
15.2 11% 3% 
Br0 N 
~(f) 
~ 
=-
~ 
ND 14 ± 2.6% 3.0 ± 3.0% 
2% 0% 
Inhibition of 
Nicotine-
evoked 
[
3 H]DA 
releasec 
19% 
ND 
23% 
20% 
aData are% inhibition at 100 nM concentration of the bis-quaternary ammonium cyclophane analogs for at least 1-3 independent experiments; with the exception 
of when a Ki value in µMis provided, in which case a full concentration effect was evaluated. Specific binding in the [3H]nicotine binding assay is calculated 
as the difference between the total binding of3 nM [3H]nicotinic and nonspecific binding in the presence of 10 µM cold cytisine. 
bSpecific binding for the [3H]MLA binding assay is calculated as the difference between the total binding of 2.5 nM [3H]MLA to the receptors alone and its 
nonspecific binding in the presence of 1 µM cold nicotine. 
cAnalog-induced inhibition of nicotine-evoked [3H]DArelease is calculated as a percent of that in the absence ofbis-quanternary ammonium cyclophane analog. 
dND indicates not determined. 
It will be appreciated that, although specific embodiments 
of the invention have been described herein for purposes of 
illustration, various modifications may be made without 
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departing from the spirit and scope of the invention. All such 
modifications and variations are intended to be included 
herein within the scope of this disclosure and the present 
invention and protected by the following claims. 
We claim: 
1. A method for selectively modulating the function of a 
nicotinic acetylcholine receptor comprising administering to 
US 9,649,301 B2 
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a mammalian subject in need thereof a therapeutically 
effective amount of a compound of Formula (I): 
(I) 5 
wherein X18 and X28 are each independently an organic 10 
or inorganic anion; 
wherein Q and T are each independently attached to R 1 
and R2 ; 
Q is alkyl; 
T is alkynyl; 15 
R 1 and R 2 are each six membered rings as shown in 
formula (IIA) 
(IIA) 20 
wherein R4 is replaced by one attachment to Qin R1 and 
R2; 
wherein Rs or R 12 is replaced by one attachment to T in 
R1 and R2 ; and 
25 
30 
wherein R6 , Rs, R10, R12, and R14 are each independently 
selected from hydrogen, lower alkyl, halo, cyano, nitro, 
trifluoromethyl, hydroxymethyl, hydroxyethyl, and 35 
hydroxypropy I. 
2. The method of claim 1, wherein transport of a com-
pound of Formula (I) into the central nervous system is 
facilitated by interaction of the compound with the blood 
brain barrier choline transporter. 
3. The method of claim 1, wherein the compound of 
Formula (I) binds selectively to one or more subtypes of the 
nicotinic acetylcholine receptors. 
40 
4. The method of claim 3, wherein the selective modula-
tion comprises activation of the function of nicotinic ace- 45 
tylcholine receptors as an agonist or as a partial agonist. 
5. The method of claim 3, wherein the selective modula-
tion comprises inactivation of the function of nicotinic 
acetylcholine receptors as an antagonist. 
6. The method of claim 3, wherein there is a decrease in 50 
the stimulant-evoked release of a neurotransmitter from a 
central nervous system tissue. 
30 
N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; 
N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium dibromide; 
N,N'-(1, 1 0-decanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; and 
N,N'-(1, 11-undecanediyl)-3,3'-(l ,9-decanediyn-1, 10-
diyl)-bis-pyridinium dibromide. 
11. A method for treating a central nervous system asso-
ciated disorder comprising administering to a manimalian 
subject in need thereof a therapeutically effective amount of 
a compound of Formula (I): 
(I) 
wherein X18 and X28 are each independently an organic 
or inorganic anion; 
wherein Q and T are each independently attached to R 1 
and R2 ; 
Q is alkyl; 
T is alkynyl; 
R1 and R2 are each six membered rings as shown m 
formula (IIA) 
(IIA) 
wherein R4 is replaced by one attachment to Qin R1 and 
R2; 
wherein Rs or R 12 is replaced by one attachment to T in 
R1 and R2 ; and 
wherein R6, Rs, R10, R12, and R14 are each independently 
selected from hydrogen, lower alkyl, halo, cyano, nitro, 
trifluoromethyl, hydroxymethyl, hydroxyethyl, and 
hydroxypropyl. 
12. The method of claim 11, wherein transport of a 
compound of Formula (I) into the central nervous system is 
facilitated by interaction of the compound with the blood 
brain barrier choline transporter. 
13. The method of claim 11, wherein the central nervous 
system associated disorder is selected from the group con-
sisting of Alzheimer's disease, dementia, cognitive dysfunc-
tions, attention deficit disorders, affective disorders, extrapy-
7. The method of claim 3, wherein there is an increase in 
the release of a neurotransmitter from a central nervous 
system tissue. 
8. The method of claim 6, wherein the neurotransmitter 
released is selected from the group consisting of dopamine, 
norepinephrine, serotonin, gamma-aminobutyric acid, and 
glutamate. 
55 ramidal motor function disorders, Parkinson's disease, 
progressive supramolecular palsy, Huntington's disease, 
Gilles de la Tourette syndrome, tardive dyskinesia, neuroen-
docrine disorders, dysregulation of food intake, disorders of 
nociception, pain, mood and emotional disorders, depres-
9. The method of claim 7, wherein the neurotransmitter 
released is selected from the group consisting of dopamine, 
norepinephrine, serotonin, gamma-aminobutyric acid, and 
glutamate. 
10. The method of claim 1, wherein the compound of 
Formula (I) is selected from the group consisting of: 
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; 
60 sion, panic anxiety, psychosis, schizophrenia, and epilepsy. 
14. The method of claim 11, wherein the compound of 
Formula (I) binds selectively to one or more subtypes of the 
nicotinic acetylcholine receptors. 
15. The method of claim 14, wherein administering the 
65 compound of Formula (I) activates the function of the 
nicotinic acetylcholine receptors as an agonist or as a partial 
agonist. 
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16. The method of claim 14, wherein administering the 
compound of Formula (I) inactivates the function of the 
nicotinic acetylcholine receptors as an antagonist. 
17. The method of claim 14, wherein there is a decrease 
in the stimulant-evoked release of a neurotransmitter from a 5 
central nervous system tissue. 
18. The method of claim 14, wherein there is an increase 
in the release of a neurotransmitter from a central nervous 
system tissue. 
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23. The method of claim 22, wherein transport of a 
compound of Formula (I) into the central nervous system is 
facilitated by interaction of the compound with the blood 
brain barrier choline transporter. 
24. The method of claim 22 wherein the substance use/ 
abuse is selected from the group consisting of nicotine 
abuse, nicotine intoxication, amphetamine abuse, metham-
phetamine abuse, MDMA abuse, methylphenidate abuse, 
cocaine abuse, and alcohol abuse. 
25. The method of claim 22, wherein the compound of 
Formula (I) binds selectively to one or more subtypes of the 
nicotinic acetylcholine receptors. 
19. The method of claim 17, wherein the neurotransmitter 10 
is selected from the group consisting of dopamine, norepi-
nephrine, serotonin, gamma-aminobutyric acid, and gluta-
mate. 26. The method of claim 25, wherein the selective modu-
lation comprises activation of the function of nicotinic 
15 acetylcholine receptors as an agonist or as a partial agonist. 
20. The method of claim 18, wherein the neurotransmitter 
is selected from the group consisting of dopamine, norepi-
nephrine, serotonin, gamma-aminobutyric acid, and gluta-
mate. 
21. The method of claim 11, wherein the compound of 
Formula (I) is selected from the group consisting of: 
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; 
N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; 
20 
27. The method of claim 25, wherein the selective modu-
lation comprises inactivation of the function of nicotinic 
acetylcholine receptors as an antagonist. 
28. The method of claim 25, wherein there is a decrease 
in the stimulant-evoked release of a neurotransmitter from a 
central nervous system tissue. 
29. The method of claim 25, wherein there is an increase 
in the release of a neurotransmitter from a central nervous N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium dibromide; 25 system tissue. 
N,N'-(1, 1 0-decanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; and 
N,N'-(1, 11-undecanediyl)-3,3'-(l ,9-decanediyn-1, 10-
diyl)-bis-pyridinium dibromide. 
22. A method for treating substance use and/or abuse 30 
comprising administering to a mammalian subject in need 
thereof a therapeutically effective amount of a compound of 
Formula (I): 
30. The method of claim 28, wherein the neurotransmitter 
released is selected from the group consisting of dopamine, 
norepinephrine, serotonin, gamma-aminobutyric acid, and 
glutamate. 
31. The method of claim 29, wherein the neurotransmitter 
released is selected from the group consisting of dopamine, 
norepinephrine, serotonin, gamma-aminobutyric acid, and 
glutamate. 
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32. The method of claim 22, wherein the compound of 
Formula (I) is selected from the group consisting of: 
(I) 
wherein X18 and X28 are each independently an organic 
or inorganic anion; 
wherein Q and T are each independently attached to R 1 
and R2 ; 
Q is alkyl; 
T is alkynyl; 
40 
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N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; 
N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; 
N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium dibromide; 
N,N'-(1, 1 0-decanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; and 
N,N'-(1, 11-undecanediyl)-3,3'-(l ,9-decanediyn-1, 10-
diyl)-bis-pyridinium dibromide. 
R 1 and R 2 are each six membered rings as shown in 
formula (IIA) 
(IIA) 
33. A method for treating gastrointestinal tract disorders 
comprising administering to a manimalian subject in need 
50 thereof a therapeutically effective amount of a compound of 
Formula (I): 
55 
wherein R4 is replaced by one attachment to Qin R1 and 60 
R2; 
wherein R 8 or R 12 is replaced by one attachment to T in 
R1 and R2 ; and 
wherein R6 , R8, R10, R12 and R14 are each independently 
selected from hydrogen, lower alkyl, halo, cyano, nitro, 65 
trifluoromethyl, hydroxymethyl, hydroxyethyl, and 
hydroxypropy I. 
(I) 
wherein X18 and X28 are each independently an organic 
or inorganic anion; 
wherein Q and T are each independently attached to R 1 
and R2 ; 
Q is alkyl; 
T is alkynyl; 
R1 and R2 are each six membered rings as shown m 
formula (IIA) 
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(IIA) 
wherein R4 is replaced by one attachment to Qin R1 and 
R2; 
wherein R 8 or R 12 is replaced by one attachment to T in 
R1 and R2 ; and 
wherein R6 , R8, R10, R12 and R14 are each independently 
selected from hydrogen, lower alkyl, halo, cyano, nitro, 
trifluoromethyl, hydroxymethyl, hydroxyethyl, and 
hydroxypropy I. 
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37. The method of claim 35, wherein the selective modu-
lation comprises inactivation of the function of nicotinic 
acetylcholine receptors as an antagonist. 
38. The method of claim 35, wherein there is a decrease 
5 in the stimulant-evoked release of a neurotransmitter from a 
central nervous system tissue. 
39. The method of claim 35, wherein there is an increase 
in the release of a neurotransmitter from a central nervous 
system tissue. 
10 
40. The method of claim 38, wherein the neurotransmitter 
released is selected from the group consisting of dopamine, 
norepinephrine, serotonin, gamma-aminobutyric acid, and 
glutamate. 
41. The method of claim 39, wherein the neurotransmitter 
released is selected from the group consisting of dopamine, 
15 norepinephrine, serotonin, gamma-aminobutyric acid, and 
glutamate. 
42. The method of claim 33, wherein the compound of 
Formula (I) is selected from the group consisting of: 
34. The method of claim 33 wherein the gastrointestinal 20 
tract disorder is selected from the group consisting of 
irritable bowel syndrome, colitis, diarrhea, constipation, 
gastric acid secretion, and ulcers. 
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; 
N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; 
N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium dibromide; 35. The method of claim 33, wherein the compound of 
Formula (I) binds selectively to one or more subtypes of the 25 
nicotinic acetylcholine receptors. 
36. The method of claim 35, wherein the selective modu-
lation comprises activation of the function of nicotinic 
acetylcholine receptors as an agonist or as a partial agonist. 
N,N'-(1, 1 0-decanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-
bis-pyridinium diiodide; and 
N,N'-(1, 11-undecanediyl)-3,3'-(l ,9-decanediyn-1, 10-
diyl)-bis-pyridinium dibromide. 
* * * * * 
